Novartis Ag (NVS) Stock Analysis and Metrics

Novartis Ag

NYSE: NVS

$153.79 ▲ +1.06 (+0.69%)

At close: Jul 17, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap113.45 Bn

P/E16,161,594,801.68

Div. Yield0.00

Total Debt (Qtr)-19.00 Mn

Add ratio to table…

About

Novartis AG is an innovative medicines company engaged in the research development manufacturing distribution marketing and sale of a broad range of pharmaceutical products. The company focuses its efforts on cardiovascular renal and metabolic diseases immunology neuroscience and oncology aiming to deliver high value medicines that alleviate society’s greatest disease burdens through technology leadership in research and development and novel access approaches. Headquartered in Basel Switzerland Novartis employs 75,267 full time equivalent employees as of December 31, 2025 and serves patients in approximately 120 countries worldwide.

Novartis generates revenue primarily from the sale of its pharmaceutical products across therapeutic areas. In 2025 the company reported net sales from continuing operations of $54.5 billion and net income from continuing operations of $14.0 billion. Its products are sold to wholesalers retailers health systems government agencies managed care organizations pharmacy benefit managers and directly to patients through prescriptions and hospital use. The global reach of its portfolio allows the company to earn income from diverse markets with a concentration in the United States and Europe.

The company operates through the following segments: Biomedical Research, Development, Operations, US Commercial, and International Commercial.

• Biomedical Research: This segment serves as the innovation engine focusing on creating new ways of fighting disease and turning scientific breakthroughs into new medicines with the potential to change lives.

• Development: This segment oversees the development of potential new medicines through clinical trials to confirm their safety and efficacy and steers the path to regulatory approval for patient use.

• Operations: This segment manufactures and delivers medicines to customers while also managing global functions such as information technology procurement and real estate services.

• US Commercial: This segment concentrates on the United States market working with customers to provide innovative medicines and services that improve treatment options and raise the quality of care for patients.

• International Commercial: This segment focuses on markets outside the United States delivering medicines and support services to healthcare providers and patients worldwide.

Within the very competitive global pharmaceutical industry Novartis positions itself as a leading innovator that competes against large multinational corporations and smaller regional players. Its competitive advantages stem from a strong research and development pipeline, a focus on high burden therapeutic areas, and the ability to pursue novel access strategies that aim to improve patient reach and affordability.

The company serves a broad customer base that includes drug wholesalers, retailers, private health systems, government agencies, managed care providers, pharmacy benefit managers, and ultimately patients who receive its medicines through prescriptions and hospital administration.

Investment Thesis

▲ Bull case

Novartis is positioning itself for sustained long-term growth through the successful expansion of its oncology and immunology franchises beyond their original indications, with Kisqali's approval in early breast cancer representing a structural shift rather than a temporary boost. The medicine's Category 1 NCCN guideline recommendation for the full study population, including node-negative patients, significantly expands the addressable market beyond metastatic breast cancer, with management noting the eligible population is approximately three times larger than what is currently labeled for competitors in early breast cancer. This is not merely an incremental indication but a foundational opportunity to deepen Kisqali's leadership in CDK4/6 inhibition, supported by strong early prescription trends showing widespread adoption and a clear path to 90% access in the early breast cancer setting, mirroring its metastatic penetration. The combination of broad label approval, robust clinical benefit demonstrated in long-term IDFS and OS trends, and favorable reimbursement expectations creates a durable growth engine that could substantially exceed current peak sales expectations, particularly as the company prepares to update its peak sales outlook at the upcoming Meet the Management event.
The radioligand therapy (RLT) platform, anchored by Pluvicto, is advancing beyond its current post-taxane metastatic castrate-resistant prostate cancer use into earlier lines of therapy and new indications, with the PSMAfore filing accepted by the FDA and a planned first-half 2025 launch set to triple the eligible patient population. Management emphasized that the real inflection point for Pluvicto will come with PSMAfore, not from current promotional efforts in the vision population, as they are preparing the market through expanded field force, DTC campaigns, and site readiness—now at 530 U.S. treatment sites—to handle the anticipated surge. Furthermore, the company is actively building manufacturing capacity in China, Japan, and the U.S., while expanding its RLT pipeline with B7-H3, Actinium, HER2, and Folate-targeted programs now in clinical stages, indicating a strategic shift from a single-product focus to a broad, diversified RLT portfolio that could become a multi-billion dollar franchise over time, significantly de-risking reliance on any single asset.
Cosentyx's performance in hidradenitis suppurativa (HS) and intravenous (IV) formulation reveals a durable competitive advantage rooted in clinical differentiation that competitors are struggling to replicate, with management highlighting that while cross-trial comparisons require caution, Cosentyx showed 60% of patients free of flares and a 50% mean reduction in pain in HS—data points that support its preeminence despite new entrants. The IV formulation, now with a permanent J-code, is seeing accelerated adoption with over 1,250 U.S. orders and 52% growth, signaling a shift toward broader utility beyond subcutaneous use. Furthermore, Novartis is pursuing two important life-cycle management opportunities in polymyalgia rheumatica and giant cell arteritis for 2025, both sizable indications that could allow Cosentyx to well exceed its current $7 billion peak sales forecast, leveraging its strong position as the leading originator biologic in the EU and China and its dynamic market leadership in HS with over 60% NBRx share in Germany. This combination of label expansion, formulation innovation, and geographic depth suggests Cosentyx's growth trajectory is more resilient and long-lasting than market models may currently assume.
Novartis's capital allocation strategy reflects a disciplined balance between returning cash to shareholders and funding high-conviction, bolt-on M&A that strengthens core platforms without overleveraging the balance sheet, with net debt below 1x EBITDA and a $16 billion net debt position against $18–19 billion of growing EBITDA providing substantial firepower. The company has been actively deploying capital into strategic areas such as RLT (via Mariana Oncology), molecular glues for immunology (via Monte Rosa Therapeutics), and AI-driven small molecule discovery (via Isomorphic Labs), while maintaining a robust share buyback program with approximately $8 billion remaining to be executed by end-2025. This approach allows Novartis to innovate externally in adjacent areas—like immunology bispecifics and trispecifics in Phase I/II—and internally advance assets such as remibrutinib and YTB for immune reset, ensuring the pipeline remains vibrant and diversified beyond reliance on internal R&D alone, which supports confidence in achieving the 5%+ CAGR guidance through 2028 even amid looming patent expiries.

Novartis is positioning itself for sustained long-term growth through the successful expansion of its oncology and immunology franchises beyond their original indications, with Kisqali's approval in early breast cancer representing a structural shift rather than a temporary boost. The medicine's Category 1 NCCN guideline recommendation for the full study population, including node-negative patients, significantly expands the addressable market beyond metastatic breast cancer, with management noting the eligible population is approximately three times larger than what is currently labeled for competitors in early breast cancer. This is not merely an incremental indication but a foundational opportunity to deepen Kisqali's leadership in CDK4/6 inhibition, supported by strong early prescription trends showing widespread adoption and a clear path to 90% access in the early breast cancer setting, mirroring its metastatic penetration. The combination of broad label approval, robust clinical benefit demonstrated in long-term IDFS and OS trends, and favorable reimbursement expectations creates a durable growth engine that could substantially exceed current peak sales expectations, particularly as the company prepares to update its peak sales outlook at the upcoming Meet the Management event.
The radioligand therapy (RLT) platform, anchored by Pluvicto, is advancing beyond its current post-taxane metastatic castrate-resistant prostate cancer use into earlier lines of therapy and new indications, with the PSMAfore filing accepted by the FDA and a planned first-half 2025 launch set to triple the eligible patient population. Management emphasized that the real inflection point for Pluvicto will come with PSMAfore, not from current promotional efforts in the vision population, as they are preparing the market through expanded field force, DTC campaigns, and site readiness—now at 530 U.S. treatment sites—to handle the anticipated surge. Furthermore, the company is actively building manufacturing capacity in China, Japan, and the U.S., while expanding its RLT pipeline with B7-H3, Actinium, HER2, and Folate-targeted programs now in clinical stages, indicating a strategic shift from a single-product focus to a broad, diversified RLT portfolio that could become a multi-billion dollar franchise over time, significantly de-risking reliance on any single asset.
Cosentyx's performance in hidradenitis suppurativa (HS) and intravenous (IV) formulation reveals a durable competitive advantage rooted in clinical differentiation that competitors are struggling to replicate, with management highlighting that while cross-trial comparisons require caution, Cosentyx showed 60% of patients free of flares and a 50% mean reduction in pain in HS—data points that support its preeminence despite new entrants. The IV formulation, now with a permanent J-code, is seeing accelerated adoption with over 1,250 U.S. orders and 52% growth, signaling a shift toward broader utility beyond subcutaneous use. Furthermore, Novartis is pursuing two important life-cycle management opportunities in polymyalgia rheumatica and giant cell arteritis for 2025, both sizable indications that could allow Cosentyx to well exceed its current $7 billion peak sales forecast, leveraging its strong position as the leading originator biologic in the EU and China and its dynamic market leadership in HS with over 60% NBRx share in Germany. This combination of label expansion, formulation innovation, and geographic depth suggests Cosentyx's growth trajectory is more resilient and long-lasting than market models may currently assume.
Novartis's capital allocation strategy reflects a disciplined balance between returning cash to shareholders and funding high-conviction, bolt-on M&A that strengthens core platforms without overleveraging the balance sheet, with net debt below 1x EBITDA and a $16 billion net debt position against $18–19 billion of growing EBITDA providing substantial firepower. The company has been actively deploying capital into strategic areas such as RLT (via Mariana Oncology), molecular glues for immunology (via Monte Rosa Therapeutics), and AI-driven small molecule discovery (via Isomorphic Labs), while maintaining a robust share buyback program with approximately $8 billion remaining to be executed by end-2025. This approach allows Novartis to innovate externally in adjacent areas—like immunology bispecifics and trispecifics in Phase I/II—and internally advance assets such as remibrutinib and YTB for immune reset, ensuring the pipeline remains vibrant and diversified beyond reliance on internal R&D alone, which supports confidence in achieving the 5%+ CAGR guidance through 2028 even amid looming patent expiries.

▼ Bear case

Despite Novartis's strong operational performance and margin expansion to 40.1% core margin in Q3, the company faces near-term revenue headwinds from looming patent expiries that are not being sufficiently offset by new launches, with Tasigna, Promacta, and Entresto all facing U.S. generic entry in mid-2025 based on current forecasting assumptions, and management explicitly noting that these losses are factored into the long-term 5% CAGR guidance through 2028—meaning the underlying growth rate of the portfolio excluding these losses may be significantly lower than advertised. While Entresto maintains strong guideline positions and protected markets in Japan (LoE not until 2031) and China, the U.S. and EU losses are material, with U.S. regulatory data protection expiring in mid-2025 and EU in November 2026, and the company's reliance on continued hypertension performance in China to offset these losses introduces geographic concentration risk, especially if reimbursement policies shift. The guidance raises have been supported by the absence of generic entries in 2024, but the real test begins in 2025 when these three major products face simultaneous erosion, potentially undermining the quality of growth if replacement products do not scale quickly enough.
The commercial potential of Fabhalta in IgA nephropathy (IgAN) remains highly uncertain despite its accelerated approval, as the drug's success is contingent on the confirmatory APPLAUSE trial meeting its primary endpoint of eGFR at 24 months—a binary outcome with no guarantee of success—and management acknowledged that the medicine is still in "early days" with utilization building slowly, noting it will take time to develop the brand even in its established PNH indication. While early signs such as over 1,000 HCPs REM certified and patient activation in Japan, U.K., and France are positive, the company is leveraging its portfolio to ensure broad access, which suggests commercial traction is not yet self-sustaining, and the expectation that Fabhalta could grow into a $3+ billion franchise across multiple indications (including C3G) depends on a series of sequential regulatory and clinical successes that are far from assured, particularly given the competitive landscape in complement inhibition and the historical difficulty of achieving broad adoption in nephrology therapies.
Pluvicto's growth outside the United States is currently hampered by pricing and reimbursement delays in key European markets like Germany and France, with management admitting that while demand generation is occurring, it is not yet translating into revenue due to ongoing negotiations, and they ex-U.S. growth is dependent on securing final pricing in China and Japan—markets where manufacturing facilities are still under construction—meaning international expansion is not imminent and could face further delays if pricing agreements are not reached. Furthermore, the company chose not to use a Priority Review Voucher for PSMAfore, citing FDA feedback that they wanted flexibility to review the 100% OS data during the standard review period, which implies confidence in the data but also suggests the approval timeline may not be meaningfully accelerated beyond typical PDUFA dates, potentially delaying the inflection point in patient eligibility that is critical to offsetting U.S. generic losses from Entresto and other assets. Without timely ex-U.S. uptake and PSMAfore approval, Pluvicto risks remaining a niche therapy confined largely to the post-taxane U.S. vision population, limiting its near-term impact.
Novartis's pivot toward siRNA therapeutics for cardiovascular indications, particularly in hypertension and as potential companions to Leqvio, carries significant execution risk given the early stage of these programs—only a couple in Phase II and one later—while the company simultaneously deprioritized its XXP (pelacarsen) program for Lp(a) after a safety signal in heart failure emerged, despite guiding to a 2025 readout, raising questions about the robustness of its late-stage cardiovascular pipeline outside of Leqvio. Although Leqvio continues to show strong growth and has a long runway ahead, the siRNA approach in hypertension has yet to demonstrate clinical validity at scale, and the company's acknowledgment that it is exploring combinations "as appropriate" suggests uncertainty about synergistic value, meaning the broader cardiovascular strategy may rely too heavily on a single asset (Leqvio) while betting on unproven modalities to replace lost income from XXP and eventually Entresto, creating a vulnerability if siRNA development stalls or fails to deliver differentiated outcomes in crowded markets.

Despite Novartis's strong operational performance and margin expansion to 40.1% core margin in Q3, the company faces near-term revenue headwinds from looming patent expiries that are not being sufficiently offset by new launches, with Tasigna, Promacta, and Entresto all facing U.S. generic entry in mid-2025 based on current forecasting assumptions, and management explicitly noting that these losses are factored into the long-term 5% CAGR guidance through 2028—meaning the underlying growth rate of the portfolio excluding these losses may be significantly lower than advertised. While Entresto maintains strong guideline positions and protected markets in Japan (LoE not until 2031) and China, the U.S. and EU losses are material, with U.S. regulatory data protection expiring in mid-2025 and EU in November 2026, and the company's reliance on continued hypertension performance in China to offset these losses introduces geographic concentration risk, especially if reimbursement policies shift. The guidance raises have been supported by the absence of generic entries in 2024, but the real test begins in 2025 when these three major products face simultaneous erosion, potentially undermining the quality of growth if replacement products do not scale quickly enough.
The commercial potential of Fabhalta in IgA nephropathy (IgAN) remains highly uncertain despite its accelerated approval, as the drug's success is contingent on the confirmatory APPLAUSE trial meeting its primary endpoint of eGFR at 24 months—a binary outcome with no guarantee of success—and management acknowledged that the medicine is still in "early days" with utilization building slowly, noting it will take time to develop the brand even in its established PNH indication. While early signs such as over 1,000 HCPs REM certified and patient activation in Japan, U.K., and France are positive, the company is leveraging its portfolio to ensure broad access, which suggests commercial traction is not yet self-sustaining, and the expectation that Fabhalta could grow into a $3+ billion franchise across multiple indications (including C3G) depends on a series of sequential regulatory and clinical successes that are far from assured, particularly given the competitive landscape in complement inhibition and the historical difficulty of achieving broad adoption in nephrology therapies.
Pluvicto's growth outside the United States is currently hampered by pricing and reimbursement delays in key European markets like Germany and France, with management admitting that while demand generation is occurring, it is not yet translating into revenue due to ongoing negotiations, and they ex-U.S. growth is dependent on securing final pricing in China and Japan—markets where manufacturing facilities are still under construction—meaning international expansion is not imminent and could face further delays if pricing agreements are not reached. Furthermore, the company chose not to use a Priority Review Voucher for PSMAfore, citing FDA feedback that they wanted flexibility to review the 100% OS data during the standard review period, which implies confidence in the data but also suggests the approval timeline may not be meaningfully accelerated beyond typical PDUFA dates, potentially delaying the inflection point in patient eligibility that is critical to offsetting U.S. generic losses from Entresto and other assets. Without timely ex-U.S. uptake and PSMAfore approval, Pluvicto risks remaining a niche therapy confined largely to the post-taxane U.S. vision population, limiting its near-term impact.
Novartis's pivot toward siRNA therapeutics for cardiovascular indications, particularly in hypertension and as potential companions to Leqvio, carries significant execution risk given the early stage of these programs—only a couple in Phase II and one later—while the company simultaneously deprioritized its XXP (pelacarsen) program for Lp(a) after a safety signal in heart failure emerged, despite guiding to a 2025 readout, raising questions about the robustness of its late-stage cardiovascular pipeline outside of Leqvio. Although Leqvio continues to show strong growth and has a long runway ahead, the siRNA approach in hypertension has yet to demonstrate clinical validity at scale, and the company's acknowledgment that it is exploring combinations "as appropriate" suggests uncertainty about synergistic value, meaning the broader cardiovascular strategy may rely too heavily on a single asset (Leqvio) while betting on unproven modalities to replace lost income from XXP and eventually Entresto, creating a vulnerability if siRNA development stalls or fails to deliver differentiated outcomes in crowded markets.

Peer Comparison

Companies in the Drug Manufacturers - General

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	LLY	ELI LILLY & Co	1,066.16 Bn	42.18	14.76	43.37 Bn
2	JNJ	Johnson & Johnson	611.69 Bn	29.07	6.35	54.99 Bn
3	ABBV	AbbVie Inc.	444.34 Bn	122.04	7.07	64.53 Bn
4	AZN	Astrazeneca Plc	284.94 Bn	23.78	2,793.52	-24.45 Bn
5	MRK	Merck & Co., Inc.	224.23 Bn	25.00	3.41	49.12 Bn
6	AMGN	Amgen Inc	195.12 Bn	25.02	5.24	57.32 Bn
7	GILD	Gilead Sciences, Inc.	156.45 Bn	16.36	5.26	22.17 Bn
8	PFE	Pfizer Inc	136.01 Bn	11,334.57	5.56	64.46 Bn

Research Tools

Developers

About

Investment Thesis

Breakdown of Revenue (2020)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Breakdown of Revenue (2020)

Peer Comparison

Create an account

Sign In

Reset Password